Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.34 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.34 |
| ▸ | CCL2 | P13500 | 1/20 | 0.34 |
| ▸ | CCL5 | P13501 | 1/20 | 0.34 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | BDNF | P23560 | 3/20 | 0.32 |
| ▸ | PTN | P21246 | 2/20 | 0.32 |
| ▸ | MDK | P21741 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11994264 | 1.00 | FGF1 (0.37) | FGF1AKT1CXCL10CXCL8CCL2 | |
| SCHEMBL19220864 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL14212353 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL14212363 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL11994265 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL23710806 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL19220861 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL14212365 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL19221011 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL19220857 | 0.94 | AKT1 (0.39) | FGF1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239397-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | UNITED STATES GOVERNMENT | 2017-08-24 | — | — | US | disclosed |
| US-20170226232-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226232-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | ALG1, FIBP, COL2A1 | FGF1 386/4885AKT1 4642/4885CXCL10 421/4885 |
| US-20170239397-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | ALG1, FIBP, COL2A1 | FGF1 386/4885AKT1 4642/4885CXCL10 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.